# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $3 price target.
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $...
Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announ...
Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 ...
2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5...
Funicular Funds has a 5.59% stake in Forte Biosciences